Hansa Biopharma AB

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:59:57 24/05/2024 pm IST			5-day change	1st Jan Change
41 ^SEK	-6.01%		+12.33%	+56.49%

18/04	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
18/04	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hansa Biopharma AB's Current Chair Ulf Wiinberg Has Chosen to Not Stand for Re-Election

May 30, 2022 at 07:41 pm IST

Hansa Biopharma AB (publ) announced that the current chair Ulf Wiinberg has chosen to not stand for re-election.

Latest news about Hansa Biopharma AB

Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04	CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04	MT
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04	CI
Hansa Biopharma Hires New CFO	22/02	MT
Hansa Biopharma AB Announces CFO Changes	22/02	CI
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02	CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02	CI
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01	CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	06/01	CI
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	15/12	CI
Hansa Biopharma Nomination Committee Formed	13/12	CI
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	07/12	CI
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	05/12	MT
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables	05/12	CI
Sweden's Hansa Biopharma CFO to Depart in February 2024	27/11	MT
Hahansa Biopharma AB Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024	27/11	CI
Transcript : Hansa Biopharma AB, Nine Months 2023 Earnings Call, Oct 26, 2023	26/23/26
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	17/23/17	MT
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant	17/23/17	CI
Hansa Biopharma to Finalize Randomization in Late-stage Kidney Study by Mid-2024	12/23/12	MT
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial	11/23/11	CI
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients	11/23/11	CI

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Companyâs operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeSâs goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Companyâs patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

27/05/2024 - Roadshow

More about the company

Income Statement Evolution

More financial data

Ratings for Hansa Biopharma AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

43.62 SEK

Average target price

105 SEK

Spread / Average Target

+140.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANSA BIOPHARMA AB	+56.49%	257M
MODERNA, INC.	+69.92%	62.86B
IQVIA HOLDINGS INC.	-0.91%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+14.49%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.81%	18.9B
BIO-TECHNE CORPORATION	+4.37%	12.67B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.27B
MEDPACE HOLDINGS, INC.	+28.99%	12.07B

Other Biotechnology & Medical Research